Sabitlenmiş Tweet
Astrangerone.eth
19.2K posts

Astrangerone.eth
@astrangerone
Indie game dev & writer. Creating Spirit Cell, a 2D pixel game about loneliness, obsession, and bending reality. Narratively driven. Emotionally charged.
A Strange Land Katılım Eylül 2021
1.7K Takip Edilen1K Takipçiler
Astrangerone.eth retweetledi
Astrangerone.eth retweetledi

Now for the find out part of FAFO
DogeDesigner@cb_doge
BREAKING: 𝕏 is now the #1 News App on the AppStore in Venezuela 🇻🇪 The people of Venezuela are receiving all the unfiltered and truthful news right here on this platform in real-time. Maduro once banned the 𝕏 app in Venezuela. Fate loves Irony.
English
Astrangerone.eth retweetledi
Astrangerone.eth retweetledi

@TiffanyFong Wait, your dad is Charlie Lee? Does that make us brother and sister?
English
Astrangerone.eth retweetledi

@TiffanyFong @higgsfield_ai Some people are going to see this and actually believe you.
English

@SoveyX I need more context as she could have had an emergency text from someone.
English

@PicturesFoIder I'd get her a plastic ring out of one of those old 25-cent vending machines that used to be at Walmart. Waste of a quarter, though, to be honest.
English

@alphafox Explain to me the logic behind making a spinning saw blade a safe place to land.
English

Who sends them their instructions!?
Real question.
Joe Rogan Podcast News@joeroganhq
Elon Musk: "Doesn't it seem weird that the legacy media all say the same thing at the same time using the same phrases?"
English


🚨🇺🇸 FDA APPROVES FIRST AT-HOME BRAIN ZAP FOR DEPRESSION - $500 HEADSET VS. DECADES OF SSRIS
Flow Neuroscience's FL-100 just became the first FDA-approved at-home brain stimulation device for depression.
Electrical current targets the mood-regulating part of your brain.
30-minute sessions. No pills. Remote supervision.
The device treats moderate to severe major depressive disorder in adults, either standalone or alongside therapy and medication.
Launches Q2 2026, prescription-only, $500-$800 retail price. Company's negotiating insurance coverage now.
The data: 58% of patients hit remission after 10 weeks in the FDA study. Many were already on meds or in therapy.
Among 55,000+ European users, 77% reported improvement within 3 weeks.
Here's what just changed:
Depression treatment has been stuck in the same paradigm for 40 years - SSRIs with their sexual dysfunction, weight gain, emotional blunting, and withdrawal nightmares.
Or therapy, which works but takes months and costs hundreds per session.
Or the nuclear option: ketamine, ECT, TMS clinics at $10K+ that insurance barely covers.
Now there's a 3rd path: buy a prescription headset, use it at home, avoid the pharmacy entirely.
The mechanism matters: This isn't placebo feel-good tech. Transcranial direct current stimulation (tDCS) has decades of research behind it.
Low electrical current literally changes neuronal firing patterns in the prefrontal cortex - the region that's underactive in depression. It's doing what SSRIs try to do chemically, but through physics instead of pharmacology.
Side effects are mostly mild - skin irritation, headache, tingling where electrodes sit. Skin burns can happen if you reuse dried-out pads like an idiot, but that's user error, not device flaw.
What this doesn't solve:
Severe, treatment-resistant depression still needs clinical intervention. Suicidal patients need immediate care, not a mail-order headset. And the 42% who didn't hit remission in the study still need other options.
But for the massive middle - people on their 2nd or 3rd SSRI, dealing with side effects, wondering if there's another way - this is the first real alternative that doesn't require weekly clinic visits or insurance pre-authorization battles.
The mental health treatment model just cracked open.
Depression's still brutal and complex. But now there's a non-pharmaceutical option that doesn't require leaving your house or dealing with side effects that wreck your sex life and make you gain 40 pounds.
That's actual progress.
Source: Reuters, Flow Neuroscience, Daily Mail


English










